Opioid use disorder

Ophelia and Vori Health Partner to Address Pain Management for Patients with Musculoskeletal Conditions

Retrieved on: 
Friday, September 22, 2023
DSM-IV codes, Partnership, Narcotic, Opioid, Addiction, Senior counsel, Therapy, Opioid use disorder, OUD, Medication, MAT, Patient, Physician, Risk, Practitioner, SUD, MSK, Nutritionist, Health, Chronic pain, Residential care, Dentistry, Nursing

MSK pain is one of the primary reasons why opioids are prescribed to patients, often by primary care physicians who are not typically trained in appropriate, evidence-based MSK care.

Key Points: 
  • MSK pain is one of the primary reasons why opioids are prescribed to patients, often by primary care physicians who are not typically trained in appropriate, evidence-based MSK care.
  • If the Vori Health care team has a patient who reports opioid addiction, they can be referred to Ophelia.
  • Conversely, if an Ophelia patient expresses concern about MSK pain and is looking for non-opioid treatment options, clinicians can refer them to Vori Health for care.
  • "By offering virtual care solutions, Vori Health can provide patients with access to evidence-based specialty care for MSK pain that cuts opioids out of the equation," said Dr. Ryan Grant , co-founder and CEO, Vori Health.

Ohio Locking Vial Program Designated Best Practice for MAT/MOUD Treatment by Leading Public Health Organization

Retrieved on: 
Tuesday, September 19, 2023
National Association of County and City Health Officials, JAMA, Medicaid, Education, Addiction, Pharmacy, Parent, Opioid use disorder, Data collection, American Medical Association, LPV, Journal, MAT, Patient, Patient safety, Channell, National Association, Safety, Nursing

The intervention was also selected for a "Best of the Best Presentation" at the NACCHO 360 annual conference.

Key Points: 
  • The intervention was also selected for a "Best of the Best Presentation" at the NACCHO 360 annual conference.
  • The intervention indicated that the use of locking prescription vials (LPVs) reduced one of the common barriers for patient participation in MOUD programs, which include accessibility, stigma, and medication safety.
  • "The intent of the intervention was to see if locking vials could be used as a tool to decrease diversion and increase patient safety and confidence.
  • "As a prescriber, I feel much more confident using the locking prescription vial for the safety of young children and families in my community.

Falsification Rate of Telemedicine-Based Urine Drug Screenings are On-Par With In-Person Treatment Programs, New Bicycle Health Study Finds

Retrieved on: 
Thursday, September 14, 2023
Telehealth, Urine, Addiction, Buprenorphine, Opioid use disorder, Drug, OUD, Research, UDS, Substance, Journal, Patient, Risk, Safety, Medical device, Phosphorus

This peer-reviewed study shows that 97.7% of study participants had no signs of sample falsification upon submitting a home-collected urine drug screen (UDS) sample by mail to a laboratory.

Key Points: 
  • This peer-reviewed study shows that 97.7% of study participants had no signs of sample falsification upon submitting a home-collected urine drug screen (UDS) sample by mail to a laboratory.
  • Bicycle Health developed a randomized at-home drug screening process that fosters accountability to necessary drug testing through a system of app-based prompts, reminders, and testing support.
  • Only 1 sample (0.8%) was a genetic mismatch from the patient’s urine sample, suggesting another person’s urine was used.
  • “Clinically-proven virtual care models like Bicycle Health have emerged as a lifeline for people struggling with OUD across this country.

Anti-Stigma Campaign – UNSHAME Kentucky – Reveals Results of Measureable Changes in Beliefs and Attitudes Toward Addiction Through Personal Stories and Education

Retrieved on: 
Tuesday, September 12, 2023
Other Philanthropy, Health, Mental Health, Philanthropy, Consumer, Other Consumer, Foundation, Other Health, Partnership, Suds, Education, Naloxone, KORE, Opioid use disorder, Hope, OUD, Research, Social isolation, Oxford, SUD, Knowledge, Drug, Commonwealth, Fentanyl, Social media, Pharmaceutical industry, Nursing, The 39 Clues

One campaign helping with those efforts is UNSHAME Kentucky , an evidence-based public health campaign that leverages community-driven stories of individuals impacted by substance use disorders (SUDs) to reduce addiction-related stigma.

Key Points: 
  • One campaign helping with those efforts is UNSHAME Kentucky , an evidence-based public health campaign that leverages community-driven stories of individuals impacted by substance use disorders (SUDs) to reduce addiction-related stigma.
  • UNSHAME Kentucky launched last year and is the result of a partnership between the Kentucky Opioid Response Effort (KORE) and Shatterproof .
  • After twelve months of campaign activity, the survey was repeated to measure change in stigma, and the results were promising.
  • Kentuckians who saw the UNSHAME Kentucky campaign held significantly lower levels of stigma toward people with OUDs compared to those who did not see the campaign.

Baron & Budd Announces $1.4 Billion Settlement From Kroger in Nationwide Opioid Lawsuit

Retrieved on: 
Saturday, September 9, 2023
Class Action Lawsuit, Professional Services, Legal, Kroger, Russell Budd, Baron & Budd, P.C., Pharmacy, NAS, Opioid use disorder, AG, Prescription, OUD, Negotiation, Heroin, Opioid, MDL, Alcohol withdrawal syndrome, Drug, Patient safety, Child, City, Baron, Cereal, State

Today, the nationally recognized attorneys at Baron & Budd announced a $1.4 billion nationwide settlement agreement with retail pharmacy giant Kroger concerning the company’s role in the opioid epidemic.

Key Points: 
  • Today, the nationally recognized attorneys at Baron & Budd announced a $1.4 billion nationwide settlement agreement with retail pharmacy giant Kroger concerning the company’s role in the opioid epidemic.
  • Baron & Budd’s President and Managing Shareholder, Russell Budd, played a lead role in negotiating the settlement.
  • When added to the previous settlements obtained from opioids manufacturers, distributors, and pharmacies, this $1.4 billion settlement with Kroger brings the total national settlement value to nearly $61.4 billion.
  • While Kroger is typically known as a grocery store, the company has more than 2,000 pharmacies within its stores nationwide.

Click Therapeutics Announces Collaboration with Indivior to Develop and Commercialize Novel Prescription Digital Therapeutics in Substance Use Disorders

Retrieved on: 
Thursday, September 7, 2023
Telemedicine, Virtual Medicine, General Health, Health, Mental Health, Artificial Intelligence, Health Technology, Technology, Apps, Applications, Opioid use disorder, Therapy, OUD, Patient, Pharmaceutical industry, Indivior

Click Therapeutics today announced the execution of a new collaboration agreement with Indivior for the development and commercialization of prescription digital therapeutics to treat substance use disorders, beginning with Opioid Use Disorder (OUD).

Key Points: 
  • Click Therapeutics today announced the execution of a new collaboration agreement with Indivior for the development and commercialization of prescription digital therapeutics to treat substance use disorders, beginning with Opioid Use Disorder (OUD).
  • Through a novel mobile application, CT-102, the collaboration aims to help close major gaps in OUD treatment, such as access to high-quality, personalized psychosocial treatment.
  • This collaboration will build on Indivior’s expertise in the commercialization of innovative treatments for substance use disorders and Click Therapeutics’ substantial real-world experience engaging patients seeking help with addiction.
  • This is the fourth major co-development and commercialization collaboration to be announced that is based on Click Therapeutics’ clinically validated platform.

Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference

Retrieved on: 
Tuesday, September 5, 2023
Health, Neurology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Ketan, Pharma, Naloxone, Oxycodone, Food and Drug Administration, Opioid use disorder, ADHD, DSM-IV codes, OUD, VAS, FQ, Physical dependence, II, Pain, Visual analogue scale, NOP, Patient, Risk, MOP, Neuropathic pain, Pain management, Addiction, Drug, HAP, FDA, Tramadol, Food, Pharmaceutical industry, Tris

Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.

Key Points: 
  • Tris Pharma, Inc. (Tris), a commercial-stage biopharmaceutical company focused on ADHD, pain and neurological disorders, today announced new data from a human abuse potential (HAP) study of cebranopadol (TRN-228) which suggest the investigational compound has significantly lower abuse potential compared to both schedule II and schedule IV opioids.
  • The findings will be shared on Thursday, September 7, in a poster presentation at the 2023 PAINWeek conference in Las Vegas.
  • Study participants randomly received a single dose of placebo, cebranopadol 600 μg, cebranopadol 1000 μg, tramadol IR 600 mg or oxycodone IR 40 mg.
  • The difference between the good effects and bad effects of drugs have been linked to their abuse potential.

BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder

Retrieved on: 
Tuesday, September 5, 2023
REMS, Mitigation, Pharmacy, Buprenorphine, Senior counsel, Health care, Opioid use disorder, Refrigeration, OUD, SL, CIII, Heroin, Stomach, Thigh, Patient, Risk, Abdomen, FDA, Disease, Pharmaceutical industry

PLYMOUTH MEETING, Pa., Sept. 5, 2023 /PRNewswire/ -- Braeburn announces that BRIXADI (buprenorphine) extended-release injection for subcutaneous use (CIII), a new weekly and monthly medication for moderate to severe opioid use disorder (OUD) in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine, is now available in the U.S. BRIXADI should be used as part of a complete treatment plan that includes counseling and psychosocial support.

Key Points: 
  • BRIXADI is the first and only injectable buprenorphine for the treatment of moderate to severe OUD that offers weekly and monthly doses.
  • "Opioid use disorder remains a public health crisis with over 82,000 people dying from an opioid overdose last year," said Mike Derkacz, President and CEO of Braeburn.
  • "We've remained committed to making another option available for healthcare providers to treat their patients with OUD, and the availability of BRIXADI is a significant milestone for Braeburn."
  • BRIXADI is the only buprenorphine injectable that utilizes FluidCrystal®* Injection Depot Technology, allowing for a low volume pre-filled syringe with a thin needle.

Pinnacle Treatment Centers Expands Addiction Treatment Services with the Opening of Canton, Georgia Location

Retrieved on: 
Thursday, August 31, 2023
Employment, Naltrexone, Senior counsel, PTC, Peach, National Association Medical Staff Services, Opioid, Patient, Pinnacle, Methadone, Opioid use disorder, Counselor, Environment, Family therapy, Family, Substance abuse, Hospital

Canton, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Canton, Georgia– 8/31/2023

Key Points: 
  • Canton, GA, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Canton, Georgia– 8/31/2023
    Pinnacle Treatment Centers (PTC) , a leading provider of comprehensive substance abuse treatment services, is pleased to announce the opening of its newest location in Canton, Georgia.
  • With a commitment to delivering personalized and evidence-based care, Pinnacle Treatment Centers aims to make a positive impact on individuals struggling with addiction in the local community.
  • Pinnacle provides underserved communities with affordable, accessible substance abuse treatment and the option of outpatient care.
  • “HealthQwest Canton offers treatment for anyone looking to escape the cycle of Opioid addiction,” says Nicole Habbe, Regional Director for Pinnacle Treatment Centers.

Albertsons & Bicycle Health Collaborate to Tackle Nation’s #1 Health Crisis - Opioid use Disorder - by Making Prescriptions Sublocade Injections Available at Over 700 Pharmacies

Retrieved on: 
Thursday, August 31, 2023
Injection, Telehealth, ER, Partnership, Health care, Buprenorphine, Pharmacy, Opioid use disorder, Health, Prescription, OUD, COVID, Privacy, Veteran, Addiction medicine, Albertsons, MD, Patient, Practitioner, Pharmaceutical industry, Nursing

MOUD is the gold-standard of care for people diagnosed with opioid use disorder (OUD).

Key Points: 
  • MOUD is the gold-standard of care for people diagnosed with opioid use disorder (OUD).
  • Buprenorphine, a partial opioid agonist, has been proven to reduce drug overdoses, ER visits, and overall healthcare costs.
  • Bicycle Health patients will have the option to have their Sublocade prescribed virtually and then receive a Sublocade injection from a pharmacist, on-site at a participating Albertsons’ pharmacy near them.
  • Bicycle Health and Albertsons plans to expand this partnership to additional states as the regulatory environment allows.